Treatment of Proliferative Versus Non-Proliferative DR

Author(s)/Faculty: W. Lloyd Clark, MD; John W. Kitchens, MD
Release Date: 6/30/2020Expiration Date: 6/29/2021
Credit Type: CME / ABO MOCNumber of Credits: 0.25
Content Type: VideoProvider:
Anti-vascular endothelial growth factor (anti-VEGF) therapy has become standard of care for many retinal diseases, such as neovascular age-related macular degeneration and diabetic retinopathy. Clinical trials continue to evaluate intravitreal anti-VEGF therapy in these retinal diseases, further refining treatment protocols, injection intervals, and dosing. Because this new data has the potential to enhance visual acuity gains and/or delay disease progression, it is imperative that these data are taken into consideration when selecting individualized treatment protocols. In this curbside consult, Dr. W. Lloyd Clark and Dr. John Kitchens evaluate the treatment of proliferative diabetic retinopathy versus non-proliferative diabetic retinopathy.